Clinical Trial

Subclinical Cardiovascular Disease in Psoriatic Disease

Study Description

Subclinical Cardiovascular Disease in Psoriatic Disease

This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) Evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional medications used in cardiovascular disease (CVD) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Aspirin and/or Atorvastatin

This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.

Additional Information

Official Study Title

Subclinical Cardiovascular Disease in Psoriatic Disease

Clinical Trial ID

NCT03228017

ParticipAid ID

negj6d